European Medicines Agency (EMA) review of data on paternal exposure to valproate
11. August 2023 – EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) is reviewing data on the potential risk of neurodevelopmental disorders (NDDs) in children conceived by fathers taking valproate medicines.
For more information, see here.